Loading
Loading
Your feedback directly shapes Sporos.
Sign in to track your feedback history
Sets forth the circumstances in which a dispenser is not required to transmit certain information to the INSPECT program (program). Requires an opioid treatment program to, before reporting patient information to the program, comply with federal regulations in obtaining patient consent. Allows the board of pharmacy to disclose prescription drug monitoring program data to a representative of the Indiana department of health and the office of the secretary of family and social services for specified purposes.
Introduced
Jan 8, 2026
Last Action
Mar 5, 2026
Session
IN 2026
Sponsors
3 primary · 2 co
Signed by the Governor
Public Law 133
Signed by the Speaker
Signed by the President Pro Tempore
Signed by the President of the Senate
Senate concurred with House amendments; Roll Call 287: yeas 47, nays 0
Returned to the Senate with amendments
Motion to concur filed
Third reading: passed; Roll Call 312: yeas 94, nays 0
Second reading: ordered engrossed
Committee report: amend do pass, adopted
First reading: referred to Committee on Public Health
Referred to the House
Third reading: passed; Roll Call 127: yeas 48, nays 0
House sponsor: Representative Goss-Reaves
Cosponsors: Representatives Barrett, Ledbetter
Amendment #2 (Crider) prevailed; voice vote
Second reading: amended, ordered engrossed
Senator Charbonneau added as second author
Committee report: amend do pass, adopted
Authored by Senator Crider
First reading: referred to Committee on Health and Provider Services
SB 262 was introduced on Jan 8, 2026 by Michael Crider in IN session 2026. It is currently signed. Most recent action on Mar 5, 2026: Signed by the Governor.
Get a plain-English explanation of what this bill does, who it affects, and why it matters.
Public Law 133